AC Immune SA (ACIU): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACIU POWR Grades
- ACIU scores best on the Value dimension, with a Value rank ahead of 55.71% of US stocks.
- The strongest trend for ACIU is in Momentum, which has been heading down over the past 31 weeks.
- ACIU's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
ACIU Stock Summary
- The ratio of debt to operating expenses for AC Immune SA is higher than it is for about just 6.58% of US stocks.
- With a year-over-year growth in debt of 269.49%, AC Immune SA's debt growth rate surpasses 96.18% of about US stocks.
- Over the past twelve months, ACIU has reported earnings growth of 881.2%, putting it ahead of 97.64% of US stocks in our set.
- Stocks that are quantitatively similar to ACIU, based on their financial statements, market capitalization, and price volatility, are USEG, MMYT, UTSI, TACT, and BB.
- ACIU's SEC filings can be seen here. And to visit AC Immune SA's official web site, go to www.acimmune.com.
ACIU Stock Price Chart Interactive Chart >
ACIU Price/Volume Stats
|Current price||$7.93||52-week high||$13.00|
|Prev. close||$7.44||52-week low||$4.42|
|Day high||$7.93||Avg. volume||764,952|
|50-day MA||$6.69||Dividend yield||N/A|
|200-day MA||$6.39||Market Cap||576.14M|
AC Immune SA (ACIU) Company Bio
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.
ACIU Latest News Stream
|Loading, please wait...|
ACIU Latest Social Stream
View Full ACIU Social Stream
Latest ACIU News From Around the Web
Below are the latest news stories about AC Immune SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile
AC Immune SA (NASDAQ: ACIU ) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No safety concerns or evidence for CNS inflammation or ARIA (amyloid-related imaging abnormalities) were observed, confirming earlier interim results. The company will complete the Phase 2 study with the 24-month … Full story available on Benzinga.com
Thinking about buying stock in AC Immune, Ashford Hospitality Trust, Sorrento Therapeutics, Jaguar Health, or Exela Technologies?
NEW YORK , June 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACIU, AHT, SRNE, JAGX, and XELA.
AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer's disease LAUSANNE, Switzerland, June 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided key clinical and preclinical updates for its SupraAntigen ® -derived liposomal vaccine candidates, which are designed to convey active, long-lasting immunization against pathological forms of amyloid-beta (Abeta). AC Immune is completing a Phase 2 study of its first clinical candidate, ACI-24, in people with mild Alzheimer's disease (AD), an...
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease LAUSANNE, Switzerland, June 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided key clinical and preclinical updates for its Su
Los Angeles, USA, May 31, 2021 (GLOBE NEWSWIRE) -- Alzheimer's Disease Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook Alzheimer's Disease pipeline shows progress in the clinical trials with the upcoming therapies such as BAN2401, Gantenerumab, Bryostatin-1, INB03, AZT-211, and others. DelveInsight's " Alzheimer's Disease Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Alzheimer's Disease pipeline landscapes. It comprises Alzheimer's Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer's Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer's Disease...
ACIU Price Returns